Andrea Seitzinger
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study.
Journal: The Lancet. Infectious diseases
Published: February 10, 2026
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 04, 2024
Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis.
Journal: Therapeutic advances in neurological disorders
Published: September 01, 2023
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 26, 2023
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Journal: Expert opinion on drug delivery
Published: June 05, 2023
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
Journal: The Lancet. Infectious diseases
Published: November 16, 2022
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Journal: European journal of neurology
Published: January 18, 2022
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.
Journal: Journal of neurology
Published: December 09, 2021
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: July 19, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026